The FDA sent warning letters to five companies for selling unapproved GLP-1 peptide products, including semaglutide, tirzepatide, and retatrutide, in interstate commerce. One company, Veronvy, was cited for misbranded oral GLP-1 products falsely claiming FDA approval. The letters target peptide vendors Xcel Peptides, Swisschems, Summit Research, and Prime Peptides. This is part of ongoing FDA enforcement against unapproved GLP-1 sales amid high demand for these drugs.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.